Free Trial
Fall Lock-In Sale! MarketBeat All Access, $149 a Year for Life
Lock In $149
Claim MarketBeat All Access Sale Promotion
NASDAQ:RNXT

RenovoRx Q3 2026 Earnings Date & Estimates

RenovoRx logo
$1.31 +0.02 (+1.55%)
Closing price 04:00 PM Eastern
Extended Trading
$1.29 -0.02 (-1.53%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

RenovoRx is estimated to report Q3 2026 earnings on Thursday, November 5, 2026, after market closes. The conference call is scheduled for 4:30 PM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
After Market Closes
Conference Call
4:30 PM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from RenovoRx in Q3 2026

RenovoRx is expected to post earnings of -$0.05 per share on revenue of $1.06 million. In the same quarter a year earlier RenovoRx reported -$0.08 per share on revenue of $266 thousand. RenovoRx last reported on August 12, 2026, posting -$0.05 per share and beating the -$0.0725 consensus estimate. RenovoRx has beaten the consensus EPS estimate in 2 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.05
Expected Revenue
$1.06 million
Prior-Year EPS
-$0.08
Prior-Year Revenue
$266 thousand
Expected Revenue Growth
+300.0%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$0.05 (Beat by +$0.0225)
Last Quarter Revenue
$909 thousand
EPS Beat Rate
2 of last 8 quarters

Prepare for the Q3 2026 Call

RenovoRx Q3 2026 Earnings FAQ

RenovoRx (NASDAQ:RNXT) is estimated to report Q3 2026 earnings on Thursday, November 5, 2026, after market closes. This date is estimated from past reporting schedules and may change once the company confirms it.

RenovoRx's Q3 2026 earnings conference call is scheduled for Thursday, November 5, 2026 at 4:30 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect RenovoRx to post earnings of -$0.05 per share for Q3 2026.

The consensus revenue estimate for RenovoRx is $1.06 million for Q3 2026.

RenovoRx Earnings Headlines

RenovoRx (NASDAQ:RNXT) Stock Rating Cut to "Sell" at Wall Street Zen
October 24 at 1:25 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31151532
RenovoRx (NASDAQ:RNXT) Shares Climb 3.3% - Here's What Happened
October 23 at 2:41 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31148451
My next big call (under $1)
17,556% on KDA. 3,900% on PRE. 2,650% on OCEAN. Every single one of these was recommended to our community before the big move happened. Now, I'm making my next big call. It's a coin under $1.00 that most investors have never heard of. But the world's largest bank is already building on it. It has a deflationary burn mechanism tied directly to institutional usage. With Bitcoin well off its highs and fear still hanging over the market, this is the exact environment where my biggest winners have been found.tc pixel
October 26 at 1:00 AM  |  Crypto 101 Media (Ad)
RenovoRx to Report Third Quarter 2026 Financial Results and Host Conference Call on November 5
October 22, 2026  |  quiverquant.comQ
RenovoRx to Report Third Quarter 2026 Financial Results and Business Highlights on November 5, 2026
October 22, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/22/3386386/0/en/renovorx-to-report-third-quarter-2026-financial-results-and-business-highlights-on-november-5-2026.html
RenovoRx Advances TAMP into Borderline Resectable Pancreatic Cancer with First Patient Enrolled in Investigator-Initiated PRISM-TAMP Trial
October 8, 2026  |  marketscreener.comM
See More RenovoRx Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like RenovoRx? Sign up for Earnings360's daily newsletter to receive timely earnings updates on RenovoRx and other key companies, straight to your email.

About RenovoRx

RenovoRx (NASDAQ:RNXT) is a clinical-stage biopharmaceutical company developing targeted treatments for solid tumors. The company’s approach is based on its Trans-Arterial Micro-Perfusion (TAMP) platform, which is designed to deliver chemotherapy directly into tumor tissue through the arterial system while limiting exposure to surrounding healthy tissue.

RenovoRx’s lead investigational product, RenovoCath, is a localized drug-delivery system intended to support the administration of anticancer therapies to tumors. The company has primarily focused on locally advanced pancreatic cancer, including the development of intra-arterial gemcitabine treatment delivered using its TAMP technology. RenovoRx has also evaluated potential applications of the platform in other solid tumors.

RenovoRx is headquartered in San Francisco, California, and conducts its development activities primarily in the United States through clinical research and collaborations with medical institutions. The company is led by Chief Executive Officer Shaun Bagai and remains focused on advancing its targeted drug-delivery platform and related oncology candidates through clinical development.

View RenovoRx Profile
Earnings Tools